Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease

Carles Gaig(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Yaroslau Compta(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Anna Heidbreder(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Marı́a José Martı́(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Maarten J. Titulaer(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Yvette S. Crijnen(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Birgit Högl(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Jan Lewerenz(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), María Elena Erro(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Juan Carlos García‐Moncó(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Pasquale Nigro(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Nicola Tambasco(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Maja Patalong‐Ogiewa(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Marcus Erdler(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Stefan Macher(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Evelyn Berger–Sieczkowski(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Romana Höftberger(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Christian Geis(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Markus Hutterer(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Ángela Milán-Tomás(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Antonio Martín‐Bastida(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Lydia López Manzanares(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Sonia Quintas(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Günter U. Höglinger(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Nora Möhn(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Florian Schöberl(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Franziska S. Thaler(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Gian Maria Asioli(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Federica Provini(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Giuseppe Plazzi(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Koldo Berganzo(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Morten Blaabjerg(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Norbert Brüggemann(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Tarsis Farias(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Chen Fei Ng(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Caroline Giordana(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Alejandro Herrero-San Martín(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Lúcio Huebra Pimentel Filho(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Katya Kotschet(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Herburg Liendl(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Teresa Montojo(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Carlos Morata(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Jesus Pérez-Pérez(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Inmaculada Puertas(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Thomas Seifert‐Held(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Caspar Seitz(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Mateus Mistieri Simabukuro(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Nieves Téllez(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Javier Villacieros‐Álvarez(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Barbara Willekens(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Lídia Sabater(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Álex Iranzo(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Joan Santamaría(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Josep Dalmau(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Francesc Graus(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer)
Neurology
August 11, 2021
Cited by 112Open Access
Full Text

Abstract

BACKGROUND AND OBJECTIVES: Anti-IgLON5 disease is a recently described neurologic disease that shares features of autoimmunity and neurodegeneration. Abnormal movements appear to be frequent and important but have not been characterized and are underreported. We describe the frequency and types of movement disorders in a series of consecutive patients with this disease. METHODS: In this retrospective, observational study, the presence and phenomenology of movement disorders were assessed with a standardized clinical questionnaire. Available videos were centrally reviewed by 3 experts in movement disorders. RESULTS: Seventy-two patients were included. In 41 (57%), the main reason for initial consultation was difficulty walking along with one or several concurrent movement disorders. At the time of anti-IgLON5 diagnosis, 63 (87%) patients had at least 1 movement disorder with a median of 3 per patient. The most frequent abnormal movements were gait and balance disturbances (52 patients [72%]), chorea (24 [33%]), bradykinesia (20 [28%]), dystonia (19 [26%]), abnormal body postures or rigidity (18 [25%]), and tremor (15 [21%]). Other hyperkinetic movements (myoclonus, akathisia, myorhythmia, myokymia, or abdominal dyskinesias) occurred in 26 (36%) patients. The craniofacial region was one of the most frequently affected by multiple concurrent movement disorders (23 patients [32%]) including dystonia (13), myorhythmia (6), chorea (4), or myokymia (4). Considering any body region, the most frequent combination of multiple movement disorders consisted of gait instability or ataxia associated with craniofacial dyskinesias or generalized chorea observed in 31 (43%) patients. In addition to abnormal movements, 87% of patients had sleep alterations, 74% bulbar dysfunction, and 53% cognitive impairment. Fifty-five (76%) patients were treated with immunotherapy, resulting in important and sustained improvement of the movement disorders in only 7 (13%) cases. DISCUSSION: Movement disorders are a frequent and leading cause of initial neurologic consultation in patients with anti-IgLON5 disease. Although multiple types of abnormal movements can occur, the most prevalent are disorders of gait, generalized chorea, and dystonia and other dyskinesias that frequently affect craniofacial muscles. Overall, anti-IgLON5 disease should be considered in patients with multiple movement disorders, particularly if they occur in association with sleep alterations, bulbar dysfunction, or cognitive impairment.


Related Papers

No related papers found

Powered by citation graph analysis